Open AccessMutations of beta-amyloid precursor protein alter the consequence of Alzheimer’s disease pathogenesis
Author(s) -
Nuomin Li,
Ke-Fu Liu,
Yunjie Qiu,
Huanhuan Zhang,
Hiroshi Nakanishi,
Hong Qing
Publication year - 2019
Publication title -
neural regeneration research/neural regeneration research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.93
H-Index - 38
eISSN - 1876-7958
pISSN - 1673-5374
DOI - 10.4103/1673-5374.247469
Subject(s) - presenilin , pathogenesis , amyloid precursor protein , amyloid beta , amyloid precursor protein secretase , mutation , alzheimer's disease , microbiology and biotechnology , alpha secretase , transfection , biology , chemistry , medicine , disease , gene , immunology , biochemistry , pathology , peptide
Alzheimer's disease is pathologically defined by accumulation of extracellular amyloid-β (Aβ). Approximately 25 mutations in β-amyloid precursor protein (APP) are pathogenic and cause autosomal dominant Alzheimer's disease. To date, the mechanism underlying the effect of APP mutation on Aβ generation is unclear. Therefore, investigating the mechanism of APP mutation on Alzheimer's disease may help understanding of disease pathogenesis. Thus, APP mutations (A673T, A673V, E682K, E693G, and E693Q) were transiently co-transfected into human embryonic kidney cells. Western blot assay was used to detect expression levels of APP, beta-secretase 1, and presenilin 1 in cells. Enzyme-linked immunosorbent assay was performed to determine Aβ 1-40 and Aβ 1-42 levels. Liquid chromatography-tandem mass chromatography was used to examine VVIAT, FLF, ITL, VIV, IAT, VIT, TVI, and VVIA peptide levels. Immunofluorescence staining was performed to measure APP and early endosome antigen 1 immunoreactivity. Our results show that the protective A673T mutation decreases Aβ 42 /Aβ 40 rate by downregulating IAT and upregulating VVIA levels. Pathogenic A673V, E682K, and E693Q mutations promote Aβ 42 /Aβ 40 rate by increasing levels of CTF99, Aβ 42 , Aβ 40 , and IAT, and decreasing VVIA levels. Pathogenic E693G mutation shows no significant change in Aβ 42 /Aβ 40 ratio because of inhibition of γ-secretase activity. APP mutations can change location from the cell surface to early endosomes. Our findings confirm that certain APP mutations accelerate Aβ generation by affecting the long Aβ cleavage pathway and increasing Aβ 42/40 rate, thereby resulting in Alzheimer's disease.